【摘要】 目的　探讨通过门静脉系统局部应用白细胞介素 12 (IL 12 )对于肝转移肿瘤的治疗作用。方法　通过门静脉注射 2× 10 5个MCA 2 0 5肿瘤细胞建立小鼠肝转移肿瘤模型 ,同时脾脏被移植到皮下 ,作为反复多次向门静脉系统注射的途径。第 3～ 7天 ,0 1μgIL 12通过腹腔或脾脏注射 ,同时对照组中通过脾脏注射等体积的平衡盐水。第 2 1天检查肝转移肿瘤的情况。结果　在肝转移模型中 ,IL 12腹腔注射组和IL 12脾脏注射组的肝脏重量 (1 33± 0 0 8)g和 (1 2 9± 0 0 7)g明显小于对照组 (1 92± 0 17)g ,P <0 0 5 ,IL 12腹腔注射组和IL 12脾脏注射组的肝脏转移结节数目 (1 5 3± 0 5 8,0 6 0± 0 89)明显少于对照组 (18 2 5± 5 71,P <0 0 5 )。在IL 12脾脏注射组中 (n =6 ) ,3只小鼠的肝脏肿瘤完全消失。结论　通过门静脉系统局部应用IL 12是治疗肝转移肿瘤的有效方法。更多还原

【Abstract】 Objective To investigate the anti tumor effect of IL 12 administration into the portal system in treatment of the liver metastasis in mice. Methods 1×10 5 of MCA 205 were injected into the portal vein to establish murine liver metastasis model, and the spleen was transpositioned subcutaneously for administration of IL 12 continually into the portal system. From day 3 to 7, 0 1 μg IL 12 was administered intraperitoneally or intra splenicly, while HBSS was injected intra splenicly in the control group. Tumors in the liver were examined on day 20. Results The liver weight in the IL 12 intraperitoneal treatment group (1 33±0 08 g) and in the IL 12 intra splenic treatment group (1 29±0 07 g) was significantly less than those in the HBSS group (1 92±0 17 g, P<0 05). The number of metastatic nodules in the IL 12 intraperitoneal treatment group (1 53±0 58) and in the IL 12 intra splenic treatment group (0 60±0 89) was significantly less than that in the HBSS group (18 25±5 71, P<0 05). Complete regression of the tumor was observed in three of six mice of IL 12 intra splenic treatment group. Conclusion Local administration of IL 12 into the portal system would be a useful strategy for the liver metastasis treatment.更多还原